A European Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Enzalutamide Treatment in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
A European Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Enzalutamide Treatment in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
The purpose of this study is to evaluate the effectiveness of enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) in the clinical practice setting as measured by time to treatment failure defined as the time from baseline (treatment initiation) to treatment discontinuation of enzalutamide for any reason including disease progression, skeletal related events, treatment toxicity, patient preference, or death.
Inclusion Criteria:
Exclusion Criteria:
Patients with the following will be excluded from study participation in France only:
Bézier, Languedoc-Roussillon 34500, France
Saint-Priest-en-Jarez, Pays de la Loire Region 42271, France
Chalon-Sus-Saone, Saône-et-Loire 71100, France
Berkshire, Slough SL2 4HL, United Kingdom
Inverness-shire, IV2 3UJ, United Kingdom
Norfolk, PE30 4ET, United Kingdom